These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25213365)
1. Update on the use of biologics in vasculitides. Vishwanath S; Relan M; Shen L; Ambrus JL Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and management of small vessel vasculitides]. Pettersson T; Karjalainen A Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753 [TBL] [Abstract][Full Text] [Related]
4. Advances in the use of biologic agents for the treatment of systemic vasculitis. Chung SA; Seo P Curr Opin Rheumatol; 2009 Jan; 21(1):3-9. PubMed ID: 19077713 [TBL] [Abstract][Full Text] [Related]
8. Targeting the B cell in vasculitis. Walsh M; Jayne D Pediatr Nephrol; 2009 Jul; 24(7):1267-75. PubMed ID: 18931860 [TBL] [Abstract][Full Text] [Related]
13. [Therapy of primary systemic vasculitis]. de Groot K; Gross WL; Hellmich B Internist (Berl); 2003 Dec; 44(12):1541-8. PubMed ID: 14689197 [TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides. Guillevin L; Pagnoux C Isr Med Assoc J; 2008 Jan; 10(1):89-91. PubMed ID: 18300585 [TBL] [Abstract][Full Text] [Related]
15. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313 [TBL] [Abstract][Full Text] [Related]
16. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. Barra L; Yang G; Pagnoux C; Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444 [TBL] [Abstract][Full Text] [Related]
17. Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Pipitone N; Olivieri I; Salvarani C; Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S139-61. PubMed ID: 22640657 [TBL] [Abstract][Full Text] [Related]
18. What place for the new biologics in the treatment of necrotising vasculitides. Jayne D Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S1-5. PubMed ID: 16859587 [No Abstract] [Full Text] [Related]
19. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Flossmann O; Jones RB; Jayne DR; Luqmani RA Ann Rheum Dis; 2006 Jul; 65(7):841-4. PubMed ID: 16769779 [TBL] [Abstract][Full Text] [Related]
20. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. de Groot K; Jayne D Clin Nephrol; 2005 Dec; 64(6):480-4. PubMed ID: 16370164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]